Ackman supports Allergan's $66B sale to Actavis

Hedge fund mogul William Ackman abandons the chase for Allergan, throwing his weight behind its $66 billion buyout by Actavis and calling off a shareholders meeting next month over his and Valeant Pharmaceuticals' hostile bid for Allergan.

Actavis, Pershing Square Capital Management, Valeant Pharmaceuticals, Allergan Inc.

News Well, Mergers & Acquisitions

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1uMjF6N